| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
|
Berenson, James R.
|
|
|
19 |
3 |
p. 343-357
|
artikel
|
| 2 |
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor
|
Evans, Louise
|
|
|
19 |
3 |
p. 333-342
|
artikel
|
| 3 |
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
|
Maris, Michael
|
|
|
19 |
3 |
p. 321-332
|
artikel
|
| 4 |
Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
|
France, Nicole L.
|
|
|
19 |
3 |
p. 481
|
artikel
|
| 5 |
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes
|
Xie, Zucheng
|
|
|
19 |
3 |
p. 383-400
|
artikel
|
| 6 |
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
|
Brazel, Danielle
|
|
|
19 |
3 |
p. 297-301
|
artikel
|
| 7 |
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
|
Uchimoto, Taizo
|
|
|
19 |
3 |
p. 401-410
|
artikel
|
| 8 |
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
|
Rimini, Margherita
|
|
|
19 |
3 |
p. 359-370
|
artikel
|
| 9 |
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
|
Onoi, Keisuke
|
|
|
19 |
3 |
p. 411-421
|
artikel
|
| 10 |
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
|
Basso, Michele
|
|
|
19 |
3 |
p. 371-382
|
artikel
|
| 11 |
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
|
Cecco, Sara
|
|
|
19 |
3 |
p. 435-445
|
artikel
|
| 12 |
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer
|
Leary, Jacob B.
|
|
|
19 |
3 |
p. 447-458
|
artikel
|
| 13 |
Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma
|
Hoy, Sheridan M.
|
|
|
19 |
3 |
p. 473-480
|
artikel
|
| 14 |
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
|
Brain, Etienne
|
|
|
19 |
3 |
p. 303-320
|
artikel
|
| 15 |
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
|
Nishioka, Naoya
|
|
|
19 |
3 |
p. 423-433
|
artikel
|
| 16 |
The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling
|
Yamamoto, Hiroyuki
|
|
|
19 |
3 |
p. 459-471
|
artikel
|
Tijdschrift beschrijving